IDEXX LABORATORIES INC (IDXX) Fundamental Analysis & Valuation
NASDAQ:IDXX • US45168D1046
608.41 USD
-10.51 (-1.7%)
At close: Mar 6, 2026
608.41 USD
0 (0%)
After Hours: 3/6/2026, 8:26:14 PM
This IDXX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
Taking everything into account, IDXX scores 7 out of 10 in our fundamental rating. IDXX was compared to 184 industry peers in the Health Care Equipment & Supplies industry. IDXX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. IDXX has a decent growth rate and is not valued too expensively. These ratings would make IDXX suitable for quality investing!
1. IDXX Profitability Analysis
1.1 Basic Checks
- In the past year IDXX was profitable.
- In the past year IDXX had a positive cash flow from operations.
- Each year in the past 5 years IDXX has been profitable.
- IDXX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- IDXX's Return On Assets of 30.34% is amongst the best of the industry. IDXX outperforms 100.00% of its industry peers.
- IDXX has a better Return On Equity (65.81%) than 100.00% of its industry peers.
- The Return On Invested Capital of IDXX (40.35%) is better than 100.00% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for IDXX is significantly above the industry average of 8.92%.
- The last Return On Invested Capital (40.35%) for IDXX is above the 3 year average (37.60%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROIC | 40.35% |
ROA(3y)28.17%
ROA(5y)27.96%
ROE(3y)59.52%
ROE(5y)79.62%
ROIC(3y)37.6%
ROIC(5y)38.02%
1.3 Margins
- With an excellent Profit Margin value of 24.65%, IDXX belongs to the best of the industry, outperforming 95.11% of the companies in the same industry.
- IDXX's Profit Margin has improved in the last couple of years.
- IDXX has a better Operating Margin (31.34%) than 98.91% of its industry peers.
- IDXX's Operating Margin has improved in the last couple of years.
- IDXX's Gross Margin of 61.72% is fine compared to the rest of the industry. IDXX outperforms 64.67% of its industry peers.
- In the last couple of years the Gross Margin of IDXX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% |
OM growth 3Y5.66%
OM growth 5Y4.24%
PM growth 3Y6.87%
PM growth 5Y2.75%
GM growth 3Y1.26%
GM growth 5Y1.26%
2. IDXX Health Analysis
2.1 Basic Checks
- IDXX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- IDXX has less shares outstanding than it did 1 year ago.
- The number of shares outstanding for IDXX has been reduced compared to 5 years ago.
- Compared to 1 year ago, IDXX has an improved debt to assets ratio.
2.2 Solvency
- IDXX has an Altman-Z score of 21.37. This indicates that IDXX is financially healthy and has little risk of bankruptcy at the moment.
- IDXX's Altman-Z score of 21.37 is amongst the best of the industry. IDXX outperforms 96.20% of its industry peers.
- The Debt to FCF ratio of IDXX is 1.04, which is an excellent value as it means it would take IDXX, only 1.04 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of IDXX (1.04) is better than 90.22% of its industry peers.
- IDXX has a Debt/Equity ratio of 0.53. This is a neutral value indicating IDXX is somewhat dependend on debt financing.
- The Debt to Equity ratio of IDXX (0.53) is comparable to the rest of the industry.
- Although IDXX's pure debt/equity ratio does not look good, it has limited outstanding debt compared to the Free Cash Flow. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Altman-Z | 21.37 |
ROIC/WACC3.99
WACC10.11%
2.3 Liquidity
- IDXX has a Current Ratio of 1.18. This is a normal value and indicates that IDXX is financially healthy and should not expect problems in meeting its short term obligations.
- IDXX's Current ratio of 1.18 is on the low side compared to the rest of the industry. IDXX is outperformed by 82.07% of its industry peers.
- A Quick Ratio of 0.87 indicates that IDXX may have some problems paying its short term obligations.
- IDXX's Quick ratio of 0.87 is on the low side compared to the rest of the industry. IDXX is outperformed by 82.07% of its industry peers.
- IDXX does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 |
3. IDXX Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an nice 16.18% over the past year.
- IDXX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 14.26% yearly.
- The Revenue has grown by 10.42% in the past year. This is quite good.
- IDXX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.72% yearly.
EPS 1Y (TTM)16.18%
EPS 3Y17.63%
EPS 5Y14.26%
EPS Q2Q%17.56%
Revenue 1Y (TTM)10.42%
Revenue growth 3Y8.52%
Revenue growth 5Y9.72%
Sales Q2Q%14.28%
3.2 Future
- The Earnings Per Share is expected to grow by 13.75% on average over the next years. This is quite good.
- IDXX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.46% yearly.
EPS Next Y13.36%
EPS Next 2Y13.1%
EPS Next 3Y13.3%
EPS Next 5Y13.75%
Revenue Next Year9.11%
Revenue Next 2Y8.86%
Revenue Next 3Y8.98%
Revenue Next 5Y9.46%
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. IDXX Valuation Analysis
4.1 Price/Earnings Ratio
- IDXX is valuated quite expensively with a Price/Earnings ratio of 46.55.
- IDXX's Price/Earnings ratio is a bit cheaper when compared to the industry. IDXX is cheaper than 69.57% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 26.29, IDXX is valued quite expensively.
- Based on the Price/Forward Earnings ratio of 41.06, the valuation of IDXX can be described as expensive.
- 68.48% of the companies in the same industry are more expensive than IDXX, based on the Price/Forward Earnings ratio.
- Compared to an average S&P500 Price/Forward Earnings ratio of 24.57, IDXX is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 46.55 | ||
| Fwd PE | 41.06 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IDXX indicates a somewhat cheap valuation: IDXX is cheaper than 67.39% of the companies listed in the same industry.
- 71.74% of the companies in the same industry are more expensive than IDXX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 51.67 | ||
| EV/EBITDA | 34.39 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- IDXX has an outstanding profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as IDXX's earnings are expected to grow with 13.30% in the coming years.
PEG (NY)3.48
PEG (5Y)3.26
EPS Next 2Y13.1%
EPS Next 3Y13.3%
5. IDXX Dividend Analysis
5.1 Amount
- No dividends for IDXX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
IDXX Fundamentals: All Metrics, Ratios and Statistics
608.41
-10.51 (-1.7%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-02 2026-02-02/bmo
Earnings (Next)04-29 2026-04-29/bmo
Inst Owners95.39%
Inst Owner Change11.43%
Ins Owners0.21%
Ins Owner Change2.2%
Market Cap48.44B
Revenue(TTM)4.30B
Net Income(TTM)1.03B
Analysts80.91
Price Target768.59 (26.33%)
Short Float %2.2%
Short Ratio3.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.14%
Min EPS beat(2)6.47%
Max EPS beat(2)7.81%
EPS beat(4)4
Avg EPS beat(4)5.72%
Min EPS beat(4)1.72%
Max EPS beat(4)7.81%
EPS beat(8)8
Avg EPS beat(8)4.83%
EPS beat(12)12
Avg EPS beat(12)4.67%
EPS beat(16)14
Avg EPS beat(16)4.04%
Revenue beat(2)2
Avg Revenue beat(2)1.45%
Min Revenue beat(2)1.03%
Max Revenue beat(2)1.88%
Revenue beat(4)3
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.88%
Revenue beat(8)3
Avg Revenue beat(8)-0.81%
Revenue beat(12)3
Avg Revenue beat(12)-1.06%
Revenue beat(16)4
Avg Revenue beat(16)-1.1%
PT rev (1m)-1.91%
PT rev (3m)-0.59%
EPS NQ rev (1m)-0.03%
EPS NQ rev (3m)0.06%
EPS NY rev (1m)0.19%
EPS NY rev (3m)2.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0.36%
Revenue NY rev (3m)2.08%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 46.55 | ||
| Fwd PE | 41.06 | ||
| P/S | 11.66 | ||
| P/FCF | 51.67 | ||
| P/OCF | 44.65 | ||
| P/B | 31.12 | ||
| P/tB | 47.04 | ||
| EV/EBITDA | 34.39 |
EPS(TTM)13.07
EY2.15%
EPS(NY)14.82
Fwd EY2.44%
FCF(TTM)11.77
FCFY1.94%
OCF(TTM)13.63
OCFY2.24%
SpS52.19
BVpS19.55
TBVpS12.93
PEG (NY)3.48
PEG (5Y)3.26
Graham Number75.83
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROCE | 61.18% | ||
| ROIC | 40.35% | ||
| ROICexc | 43.87% | ||
| ROICexgc | 56.38% | ||
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% | ||
| FCFM | 22.56% |
ROA(3y)28.17%
ROA(5y)27.96%
ROE(3y)59.52%
ROE(5y)79.62%
ROIC(3y)37.6%
ROIC(5y)38.02%
ROICexc(3y)42.72%
ROICexc(5y)42.26%
ROICexgc(3y)50.78%
ROICexgc(5y)53.04%
ROCE(3y)53.41%
ROCE(5y)55.15%
ROICexgc growth 3Y-1.85%
ROICexgc growth 5Y-3.56%
ROICexc growth 3Y7.2%
ROICexc growth 5Y1.43%
OM growth 3Y5.66%
OM growth 5Y4.24%
PM growth 3Y6.87%
PM growth 5Y2.75%
GM growth 3Y1.26%
GM growth 5Y1.26%
F-Score8
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Debt/EBITDA | 0.57 | ||
| Cap/Depr | 105.48% | ||
| Cap/Sales | 3.55% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 75.23% | ||
| Profit Quality | 91.51% | ||
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 | ||
| Altman-Z | 21.37 |
F-Score8
WACC10.11%
ROIC/WACC3.99
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)3.3%
Cap/Sales(5y)3.67%
Profit Quality(3y)93.71%
Profit Quality(5y)84.62%
High Growth Momentum
Growth
EPS 1Y (TTM)16.18%
EPS 3Y17.63%
EPS 5Y14.26%
EPS Q2Q%17.56%
EPS Next Y13.36%
EPS Next 2Y13.1%
EPS Next 3Y13.3%
EPS Next 5Y13.75%
Revenue 1Y (TTM)10.42%
Revenue growth 3Y8.52%
Revenue growth 5Y9.72%
Sales Q2Q%14.28%
Revenue Next Year9.11%
Revenue Next 2Y8.86%
Revenue Next 3Y8.98%
Revenue Next 5Y9.46%
EBIT growth 1Y17.46%
EBIT growth 3Y14.66%
EBIT growth 5Y14.37%
EBIT Next Year22.71%
EBIT Next 3Y14.82%
EBIT Next 5Y15.18%
FCF growth 1Y18.62%
FCF growth 3Y40.13%
FCF growth 5Y14.37%
OCF growth 1Y18.68%
OCF growth 3Y29.59%
OCF growth 5Y12.77%
IDEXX LABORATORIES INC / IDXX FAQ
What is the ChartMill fundamental rating of IDEXX LABORATORIES INC (IDXX) stock?
ChartMill assigns a fundamental rating of 7 / 10 to IDXX.
What is the valuation status of IDEXX LABORATORIES INC (IDXX) stock?
ChartMill assigns a valuation rating of 4 / 10 to IDEXX LABORATORIES INC (IDXX). This can be considered as Fairly Valued.
Can you provide the profitability details for IDEXX LABORATORIES INC?
IDEXX LABORATORIES INC (IDXX) has a profitability rating of 9 / 10.
What are the PE and PB ratios of IDEXX LABORATORIES INC (IDXX) stock?
The Price/Earnings (PE) ratio for IDEXX LABORATORIES INC (IDXX) is 46.55 and the Price/Book (PB) ratio is 31.12.
What is the expected EPS growth for IDEXX LABORATORIES INC (IDXX) stock?
The Earnings per Share (EPS) of IDEXX LABORATORIES INC (IDXX) is expected to grow by 13.36% in the next year.